Diabetes symptoms are easy to miss, because the earliest ones — thirst that never quite settles, frequent trips to the bathroom, tiredness, blurred vision — look like ordinary fatigue. What settles the question is not how you feel but what your blood glucose does, measured with a small number of standardized tests. In this article you will learn which diabetes symptoms deserve attention, what fasting plasma glucose, the two-hour glucose tolerance test, HbA1c and a random glucose measurement each show, and the cut points separating a normal result from prediabetes and diabetes. You will also see when HbA1c cannot be trusted, how clinicians tell type 1 from type 2, which follow-up tests belong on a yearly checklist, and what current treatment realistically offers.
What diabetes is, and why blood sugar rises
Diabetes is a group of conditions in which glucose stays too high because insulin is missing, no longer works well, or both. Insulin is the hormone made by beta cells in the pancreas, and it acts like a key that lets glucose move out of the bloodstream into muscle, fat and liver cells. When that fails, glucose accumulates, spills into the urine and pulls water with it — which is why the classic diabetes symptoms revolve around thirst and urination. The label matters, because two people with an identical HbA1c can need completely different treatment.
Type 1 diabetes
The immune system destroys the insulin-producing beta cells, so insulin must be replaced from the day of diagnosis. Type 1 often appears in childhood but can begin at any age, including in the fifties, where it is frequently mistaken for type 2. Onset is usually rapid: heavy thirst, weight loss despite a normal appetite, and sometimes diabetic ketoacidosis, an emergency in which the body burns fat and floods the blood with acid.
Type 2 diabetes
Type 2 begins with insulin resistance: cells respond poorly to insulin, so the pancreas makes more. The numbers look acceptable for years, until beta cells cannot keep pace. This is the most common form, and it is why many people are diagnosed on a routine blood panel rather than because they felt unwell.
Gestational and other forms
Gestational diabetes is high blood glucose first recognized during pregnancy, driven by placental hormones that blunt insulin action. It rarely causes noticeable diabetes symptoms, usually resolves after delivery, and raises the mother’s later risk of type 2 diabetes. A few cases fit none of these boxes: monogenic diabetes, diabetes after pancreatitis, and steroid-induced diabetes.
Diabetes symptoms, and which ones need urgent care
The common early signs
The diabetes symptoms that show up most often are easy to rationalize away:
- Passing urine more often, including waking at night to do it
- Thirst that returns quickly after drinking
- Fatigue that rest does not fix
- Blurred vision that comes and goes as glucose swings
- Unintended weight loss, particularly in type 1
- Cuts, gum infections or skin infections that heal slowly
- Tingling, burning or numbness in the feet
- Recurrent thrush or urinary tract infections
Prediabetes usually produces none of these. In type 1 the picture develops over days to weeks; in type 2 it can take years, and the first clue is sometimes a complication instead — numb feet, a change in vision, an unexpected laboratory result.
When to see a doctor
Book a routine appointment if diabetes symptoms such as thirst, urination, fatigue or blurred vision have lasted more than a couple of weeks, or if you have risk factors and have never been tested. Seek same-day or emergency care for nausea and vomiting with deep rapid breathing, fruity-smelling breath, abdominal pain, confusion or drowsiness alongside high glucose — these suggest diabetic ketoacidosis. Home strips can detect urine ketones, and a positive strip with vomiting is a reason to call for help rather than wait.
How diabetes is diagnosed: four tests and one confirmation rule
Diagnosis rests on four measurements, each looking at glucose over a different time frame.
Fasting plasma glucose
A blood sample drawn after at least eight hours with no food or caloric drinks, capturing what the liver releases overnight. A separate article walks through the fasting glucose test in detail.
The two-hour oral glucose tolerance test
You fast, a baseline sample is drawn, you drink a solution containing 75 grams of glucose, and blood is drawn again two hours later. It is a stress test for the pancreas, and it catches people whose fasting value still looks acceptable — hence its place in pregnancy and ambiguous cases.
HbA1c
HbA1c, or glycated hemoglobin, measures the proportion of hemoglobin molecules inside red blood cells that carry attached glucose. Because red cells live roughly three months, it reflects average glucose over the previous two to three months, weighted toward recent weeks. It needs no fasting, but for a diagnosis it must come from a method certified by the National Glycohemoglobin Standardization Program. Readers wanting the measurement unpacked can consult a detailed guide to glycated hemoglobin results.
Random plasma glucose
A sample taken at any moment, without regard to meals. Alone it cannot rule diabetes in or out — but 200 mg/dL or above in someone with classic symptoms of high blood sugar, or in a hyperglycemic crisis, is diagnostic immediately.
| Test | Normal | Prediabetes | Diabetes |
|---|---|---|---|
| Fasting plasma glucose | 99 mg/dL or below | 100 to 125 mg/dL | 126 mg/dL or above |
| Two-hour glucose tolerance test (75 g) | 139 mg/dL or below | 140 to 199 mg/dL | 200 mg/dL or above |
| HbA1c | Below 5.7 percent | 5.7 to 6.4 percent | 6.5 percent or above |
| Random plasma glucose | Not used for staging | Not used for staging | 200 mg/dL or above with classic symptoms |
These cut points are published by the Centers for Disease Control and Prevention and match the criteria used by American laboratories.
The confirmation rule
One abnormal number is not a diagnosis. Unless glucose is unequivocally high alongside classic symptoms, the result must be confirmed — by repeating the same test on a second sample, or by finding two different abnormal tests on one blood draw, such as a fasting glucose of 130 mg/dL with an HbA1c of 6.7 percent. If two tests disagree, the one that crossed the threshold is repeated.
Screening, including in pregnancy
Because type 2 diabetes runs silently for years, screening does not wait for diabetes symptoms: testing is recommended for all adults from age 35, and earlier for people carrying extra weight who also have a family history, previous gestational diabetes, polycystic ovary syndrome or physical inactivity. If normal, retest every three years. In pregnancy, screening happens between 24 and 28 weeks: the one-step approach uses a 75 gram tolerance test, where one value at or above 92 mg/dL fasting, 180 mg/dL at one hour or 153 mg/dL at two hours makes the diagnosis; the two-step approach screens with a 50 gram drink and sends only results above roughly 130 to 140 mg/dL on to a longer 100 gram test.
When HbA1c cannot be trusted
HbA1c is indirect: it infers average glucose from how long red blood cells live and what hemoglobin they carry. Anything that changes red cell lifespan or hemoglobin structure shifts the result without glucose having moved. The situations to flag:
- Anemia, particularly iron deficiency, which tends to push HbA1c upward, and hemolytic anemia, which pushes it downward
- Hemoglobin variants such as hemoglobin S, C, E or D, which interfere with certain assay methods
- A recent blood transfusion or recent significant blood loss, which mixes red cells of different ages
- The second and third trimesters of pregnancy, where red cell turnover accelerates
- Advanced chronic kidney disease, dialysis, and treatment with erythropoiesis-stimulating agents
- Any rapid change in glucose over days to weeks, which HbA1c is too slow to register
When one of these applies, diagnosis falls back on plasma glucose rather than HbA1c. For short-term monitoring, laboratories can substitute a fructosamine test, which reflects the previous two to three weeks and is unaffected by red cell lifespan.
Sorting out the type when it is not obvious
A slim adult in their forties with rapidly rising glucose, or a teenager with obesity and a gradual onset, is easily misclassified. Two laboratory tools settle it.
Islet autoantibodies
These are immune proteins aimed at the pancreas, and finding them points to type 1. The panel covers antibodies against glutamic acid decarboxylase, tyrosine phosphatase IA-2, zinc transporter 8 and insulin itself. A positive result in an adult suggests the slowly progressing form called latent autoimmune diabetes in adults; a negative panel does not fully exclude type 1 but makes it much less likely.
C-peptide
The pancreas releases C-peptide, a fragment cut from the insulin precursor, in equal amounts with its own insulin. Because injected insulin contains none, measuring it shows how much the body still produces. A low or undetectable value with high glucose points to type 1; a normal or high value points to insulin resistance and type 2. It is paired with a glucose measurement drawn at the same moment. Your clinician may order a C-peptide blood test when the treatment decision hinges on the answer.
The monitoring panel after diagnosis
After diagnosis, follow-up is less about glucose alone and more about the organs glucose damages quietly. Kidney, eye and nerve damage begin long before new diabetes symptoms appear, which is why the schedule below is fixed rather than symptom-driven.
| Check | Typical interval | What it tells you |
|---|---|---|
| HbA1c | Twice a year when stable and at target; every three months otherwise | Average glucose over roughly two to three months |
| Urine albumin-to-creatinine ratio | At least once a year | The earliest detectable sign of kidney damage |
| eGFR from serum creatinine | At least once a year | How well the kidneys are filtering |
| Lipid panel | Usually once a year | Cholesterol and triglyceride contribution to arterial risk |
| Blood pressure | Every routine visit | Pressure load on kidneys, eyes and heart |
| Dilated retinal examination | At diagnosis in type 2, within five years in type 1, then yearly | Retinal damage long before vision changes |
| Comprehensive foot examination | At least once a year, with a look at every visit | Loss of protective sensation and reduced circulation |
Kidney screening is the check most often skipped. It combines a urine albumin-to-creatinine ratio with an estimated glomerular filtration rate; two abnormal urine results three months apart, or a persistently reduced filtration rate, define kidney damage, and a dedicated article covers chronic kidney disease. Cardiovascular risk travels with diabetes, so most reviews include a full lipid panel. Many people with type 2 diabetes also carry a high cholesterol diagnosis, and we cover high blood pressure management separately. Autoimmune thyroid disease clusters with type 1, and another article explains hypothyroidism and its symptoms.
Continuous glucose monitoring and time in range
A continuous glucose monitor is a small sensor worn on the arm or abdomen that samples the fluid between cells every few minutes and streams a curve to a phone. It shows what a single HbA1c cannot: when highs and lows happen, and how meals, exercise, illness and doses move the line. Its headline number is time in range — the share of the day spent between 70 and 180 mg/dL. For most non-pregnant adults the target is more than 70 percent of the day in that band, with less than 4 percent below 70 mg/dL and less than 1 percent below 54 mg/dL. Sensors also report a glucose management indicator, an HbA1c-like estimate calculated from sensor data; the two figures often disagree by a few tenths of a percent, and neither is simply wrong. Continuous monitoring is genuinely useful for anyone on insulin and increasingly useful for others, but it spots patterns rather than replacing the tests that establish a diagnosis.
Treatment as it stands today
Type 1 diabetes
Insulin replacement is not optional. Most people use a long-acting background insulin plus rapid-acting doses at meals, or a pump. Automated insulin delivery systems, pairing a pump with a continuous sensor, are now standard in many clinics. Carbohydrate counting, hypoglycemia planning and sick-day rules matter as much as the medication.
Type 2 diabetes
Treatment aims at far more than relieving diabetes symptoms. Nutrition, activity, sleep and weight management remain the foundation, and metformin is still the usual first medication. What changed in the last decade is that two drug classes are now chosen for organ protection, not glucose alone.
- SGLT2 inhibitors make the kidneys excrete glucose in the urine. They are recommended for type 2 diabetes with chronic kidney disease, heart failure or established cardiovascular disease, whatever the HbA1c, because they slow kidney decline and reduce heart failure hospitalizations.
- GLP-1 receptor agonists mimic a gut hormone that increases insulin release after meals, slows stomach emptying and reduces appetite. They lower glucose, produce meaningful weight loss and reduce major cardiovascular events in people at high risk. Dual GIP and GLP-1 agents act on two pathways at once.
These are real advances, not miracle cures. They cost more than older drugs and carry side effects: nausea and vomiting are common with GLP-1 agents, while SGLT2 inhibitors raise the risk of genital yeast infections and, rarely, ketoacidosis at near-normal glucose. Sulfonylureas, pioglitazone and insulin still have a place, and a non-steroidal mineralocorticoid receptor antagonist may be added when kidney disease is present.
Gestational diabetes, prediabetes and remission
Gestational diabetes is usually managed with dietary change and self-monitoring, with insulin added when targets are not met; testing is repeated 4 to 12 weeks after delivery and then at least every three years. Prediabetes is where the trajectory is most modifiable, since structured programs combining modest weight loss with regular activity substantially cut progression to type 2 diabetes. In established type 2 diabetes, significant weight loss can bring glucose below the diabetes threshold without medication — remission rather than cure, since monitoring continues and relapse is possible.
Latest scientific advances
Research from the past three years has focused less on new thresholds and more on knowing when to trust a number, and on which medicines protect organs.
A checklist for when HbA1c disagrees with glucose
A 2026 clinical review in the Southern Medical Journal listed the common reasons an HbA1c does not match measured glucose — iron deficiency, kidney disease, altered red blood cell turnover, hemoglobin variants and rapid recent swings — and set out how to investigate rather than immediately increase medication. A 2025 review in Diabetic Medicine did the same for sensor-derived estimates, and a 2024 analysis in Diabetes Care found that two weeks of sensor data combined with an HbA1c estimates true average glucose better than either alone. What this means for you: a mismatch between your HbA1c and your sensor or home readings is a recognized situation worth naming out loud, and bringing both to a review describes your control better than either alone.
Continuous monitoring helps in type 2 diabetes, not just type 1
A 2024 systematic review and meta-analysis in Diabetologia — a systematic review pools separate trials to see whether they agree — found that adults with type 2 diabetes using a sensor instead of fingersticks had modestly better average glucose and spent roughly an extra hour and a half a day in the target range. A larger 2025 pooled analysis in Diabetes Technology and Therapeutics reached similar conclusions across type 1, type 2 and pregnancy. What this means for you: a sensor is reasonable to discuss if patterns are hard to see, though these trials were short and did not measure long-term complications.
Newer glucose-lowering drugs protect the heart and kidneys
A 2024 pooled analysis in the European Stroke Journal, covering tens of thousands of people with type 2 diabetes, found that GLP-1 receptor agonists and the dual GIP and GLP-1 agent tirzepatide reduced major cardiovascular events and deaths from any cause by roughly an eighth compared with placebo, with a clear drop in ischemic stroke. A 2025 network analysis in Frontiers in Pharmacology — which compares treatments indirectly when they have not been tested head to head — looked at people with type 2 diabetes and kidney disease not yet needing dialysis, and found that SGLT2 inhibitors, GLP-1 receptor agonists and the mineralocorticoid blocker finerenone each improved different parts of the picture. What this means for you: when diabetes comes with kidney, heart or vascular disease, medication choice is now partly about organ protection. Both findings pool trial data rather than resting on one definitive study, so guidelines keep evolving.
Glossary
| Term | Definition |
|---|---|
| HbA1c (glycated hemoglobin) | The share of hemoglobin molecules carrying attached glucose. It reflects average blood sugar over roughly the previous two to three months. |
| Fasting plasma glucose | A blood glucose measurement taken after at least eight hours without food or caloric drinks. |
| Oral glucose tolerance test (OGTT) | A test in which blood glucose is measured before and two hours after drinking a standard sugary solution, showing how quickly the body clears a glucose load. |
| C-peptide | A fragment released in equal amounts with the body’s own insulin. Measuring it shows how much insulin the pancreas is still producing. |
| Islet autoantibody | An immune protein directed against the insulin-producing cells of the pancreas. Its presence points toward type 1 diabetes. |
| Insulin resistance | A state in which muscle, fat and liver cells respond poorly to insulin, so the pancreas must produce more to keep glucose normal. |
| Time in range | The percentage of the day a continuous sensor records glucose between 70 and 180 mg/dL. |
| Glucose management indicator (GMI) | An estimate of HbA1c calculated from continuous sensor data. It often differs slightly from the laboratory value. |
| Urine albumin-to-creatinine ratio (uACR) | A urine test comparing albumin to creatinine. A rising ratio is the earliest laboratory sign of diabetic kidney damage. |
| Diabetic ketoacidosis (DKA) | A medical emergency in which a severe lack of insulin forces the body to burn fat, producing acids called ketones that build up in the blood. |
Frequently asked questions
What are the earliest warning signs of diabetes?
The signs people notice first are increased urination, persistent thirst, tiredness, blurred vision, slow-healing cuts, recurrent infections and tingling in the feet. Unintended weight loss is more typical of type 1. None of these is specific — all can have other explanations — and prediabetes often produces none at all. That combination is why a blood test rather than a symptom checklist is the only way to know. If any of these have lasted more than a couple of weeks, ask for a fasting glucose or an HbA1c.
Can one high blood sugar reading mean I have diabetes?
Usually not. Apart from one specific situation — a random glucose of 200 mg/dL or above in someone with classic symptoms of high blood sugar — a single abnormal number needs confirmation. That confirmation can be a repeat of the same test on a new sample, or two different abnormal tests on one blood draw. Stress, acute illness, steroid medication and a recent large meal can all push a single reading up temporarily.
What is a normal A1C for someone without diabetes?
Below 5.7 percent is considered normal. From 5.7 to 6.4 percent falls in the prediabetes range, and 6.5 percent or above meets the diabetes threshold when confirmed. Keep in mind that an HbA1c is an average: it can look reassuring while masking real highs after meals and real lows overnight, which is one reason clinicians sometimes ask for glucose measurements as well.
Are diabetes symptoms different in women?
The core symptoms are the same in everyone. Some patterns are more common in women, including recurrent vaginal thrush and urinary tract infections driven by glucose in the urine. A history of gestational diabetes or of polycystic ovary syndrome also raises later risk, which changes when screening should start rather than what the symptoms look like.
Can prediabetes be reversed?
Often, yes. Sustained changes in eating patterns and physical activity, with modest weight loss where relevant, return many people to a normal fasting glucose and HbA1c and substantially reduce progression to type 2 diabetes. Because prediabetes can return, retesting once a year is the usual advice even after the numbers normalize.
Do I need a fasting test, or is an HbA1c enough?
Either can diagnose diabetes, and HbA1c is more convenient because it needs no fasting. However, HbA1c is not reliable in anemia, in the presence of hemoglobin variants, after a transfusion, in later pregnancy, or in advanced kidney disease — in those situations glucose measurements take over. If your two results disagree, that is a recognized problem and worth discussing rather than ignoring.
Sources
- Centers for Disease Control and Prevention — Diabetes Testing — https://www.cdc.gov/diabetes/diabetes-testing/index.html
- National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) — Diabetes Tests and Diagnosis — https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis
- Mayo Clinic — Diabetes: Diagnosis and Treatment — https://www.mayoclinic.org/diseases-conditions/diabetes/diagnosis-treatment/drc-20371451
- Burroughs B — When HbA1c Lies: Recognizing and Managing HbA1c-Glucose Discordance in Clinical Practice — Southern Medical Journal, 2026 — https://doi.org/10.14423/SMJ.0000000000002002
- Lenters-Westra E, Fokkert M, Kilpatrick ES, Schleicher E, Pilla S, English E, van Dijk P — Managing discordance between HbA1c and glucose management indicator — Diabetic Medicine, 2025 — https://doi.org/10.1111/dme.70023
- Tozzo V, Genco M, Cohen RM, Nathan DM, Wexler DJ, Higgins JM, et al. — Estimating Glycemia From HbA1c and CGM: Analysis of Accuracy and Sources of Discrepancy — Diabetes Care, 2024 — https://doi.org/10.2337/dc23-1177
- Jancev M, Vissers TACM, Visseren FLJ, van Sloten TT, et al. — Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis — Diabetologia, 2024 — https://doi.org/10.1007/s00125-024-06107-6
- Rizos EC, Markozannes G, Charitakis N, Nørgaard K, Ntzani EE, Tsilidis KK, et al. — Continuous Glucose Monitoring in Type 1 Diabetes, Type 2 Diabetes, and Diabetes During Pregnancy: A Systematic Review with Meta-Analysis of Randomized Controlled Trials — Diabetes Technology and Therapeutics, 2025 — https://doi.org/10.1089/dia.2024.0599
- Stefanou MI, Theodorou A, Palaiodimou L, Lambadiari V, Siasos G, Tsivgoulis G, et al. — Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: a systematic review and meta-analysis — European Stroke Journal, 2024 — https://doi.org/10.1177/23969873241234238
- Guo J, Wei M, Zhang W, Jiang Y, Yin D, Gong Y, et al. — Clinical efficacy and safety of SGLT-2 inhibitors, GLP-1 receptor agonists and finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials — Frontiers in Pharmacology, 2025 — https://doi.org/10.3389/fphar.2025.1517272
Further reading
- Early insulin resistance signs and tests before A1c rises
- Estimated average glucose and what eAG means
- Glucose in a urine test and how to read the result
- A complete blood count and what its values mean
- A clear patient guide to reading lab results
Understand your lab results with BloodSense
A diabetes work-up rarely arrives as a single number. It usually comes back as a page holding a fasting glucose, an HbA1c, a lipid panel, a creatinine with an estimated filtration rate, and a urine albumin-to-creatinine ratio — each with its own reference range and its own caveats. BloodSense reads that page with you, explains what each value measures, flags which results sit outside their range and which combinations deserve a question at your next appointment. It helps you understand your results and prepare better conversations; it does not diagnose, and it does not replace your doctor.
